Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H11ClO3 |
| Molecular Weight | 226.656 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1
InChI
InChIKey=ARHWPKZXBHOEEE-UHFFFAOYSA-N
InChI=1S/C11H11ClO3/c1-2-5-15-10-4-3-8(6-9(10)12)7-11(13)14/h2-4,6H,1,5,7H2,(H,13,14)
| Molecular Formula | C11H11ClO3 |
| Molecular Weight | 226.656 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/21068Curator's Comment: description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/26888
https://www.gov.uk/drug-safety-update/aceclofenac-preservex-updated-cardiovascular-advice-in-line-with-diclofenac-and-cox-2-inhibitors
Sources: http://www.ncbi.nlm.nih.gov/pubmed/21068
Curator's Comment: description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/26888
https://www.gov.uk/drug-safety-update/aceclofenac-preservex-updated-cardiovascular-advice-in-line-with-diclofenac-and-cox-2-inhibitors
Alclofenac (Preservex) is a non-steroidal anti-inflammatory agent advocated for use in rheumatoid arthritis, degenerative joint disease and ankylosing spondylitis. Aceclofenac has little pharmacological activity itself; its main mode of action is through its metabolites which include diclofenac and 4’-hydroxy diclofenac. Skin rash is the most frequent side-effect, which in a small proportion of affected patients may be associated with systemic effects. A cutaneous reaction appears to be more likely in patients with a history of previous allergy to penicillin and other drugs. In June 2013 was told about the new contraindications and warnings for diclofenac. This was after a review by European regulators concluded that the risk of arterial thrombotic events (myocardial infarction; stroke) with diclofenac is greater than with other non-selective NSAIDs and similar to the COX-2 inhibitors.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | PRINALGIN Approved UseUnknown |
|||
| Primary | PRINALGIN Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/4281380 |
Primary | PRINALGIN Approved UseUnknown |
||
| Primary | PRINALGIN Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. | 2009-09 |
|
| Percutaneous permeation enhancement by terpenes: mechanistic view. | 2008 |
|
| Non-steroidal anti-inflammatory drugs for heavy bleeding or pain associated with intrauterine-device use. | 2006-10-18 |
|
| Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. | 2001-05-01 |
|
| Skin sensitizing properties of arylalcanoic acids and their analogues. | 1979-09 |
|
| Renal papillary necrosis after aspirin and alclofenac. | 1977-12-10 |
|
| The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis. | 1975 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.medicines.org.uk/emc/medicine/26888
The recommended dose is 200 mg daily, taken as two separate 100 mg doses, one tablet in the morning and one in the evening
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6141199
Alclofenac showed no mutagenic, transforming or clastogenic potential in any in vitro experiment.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:42:27 GMT 2025
by
admin
on
Wed Apr 02 09:42:27 GMT 2025
|
| Record UNII |
M9CP5H21N8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QM01AB06
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
||
|
WHO-ATC |
M01AB06
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
31183
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
PRIMARY | |||
|
30951
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
PRIMARY | |||
|
m1004
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
PRIMARY | Merck Index | ||
|
107
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
PRIMARY | |||
|
C174701
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
PRIMARY | |||
|
100000087734
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
PRIMARY | |||
|
2826
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
PRIMARY | |||
|
244-795-4
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
PRIMARY | |||
|
DTXSID4020038
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
PRIMARY | |||
|
CHEMBL94081
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
PRIMARY | |||
|
DB13167
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
PRIMARY | |||
|
M9CP5H21N8
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
PRIMARY | |||
|
22131-79-9
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
PRIMARY | |||
|
SUB05299MIG
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
PRIMARY | |||
|
ALCLOFENAC
Created by
admin on Wed Apr 02 09:42:27 GMT 2025 , Edited by admin on Wed Apr 02 09:42:27 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |